Some examples include:Ĭonsulting fees that companies pay to doctors, to get their input about their products and researchĬompanies paying doctors to speak about their products at conferencesĬompanies taking doctors out to dinner to tell them about a new drug or medical deviceĬompanies paying for travel, hotel rooms, and food at medical conferences government collects extensive records about these relationships. This section shows the financial relationships between doctors and pharmaceutical and medical device companies. More questions? You can always contact us.
Always check with your doctor before making any decisions. It may also be skewed towards procedures more common among Medicare beneficiaries than the general population.Ī lack of detection does not necessarily mean a lack of expertise, just that it was not visible within this dataset. The data is limited to Medicare beneficiaries, meaning that physicians that do not accept Medicare (<10% of all physicians) will be excluded. While this data can provide a wealth of knowledge, it comes with certain limitations. These procedures go into this section in order to help consumers make more informed choices. Using this data, we can detect when doctors perform certain procedures more frequently than similar providers. It includes aggregate information about the procedures performed by different providers.
This feature uses Medicare data to determine how often a provider performs a procedure relative to other providers in their state also performing the same procedure.ĭata in this section is calculated using Medicare Physician and Other Supplier Data, which provides records of Medicare utilization throughout the United States. Starting ppFEV 1 was lower in those with a high to higher trajectory, supporting that lower lung function is present early in the development of CFRD.This section highlights the procedures that Dr. DiscussionĪmong pediatric CF patients without diabetes, three 2hrGlu trajectories were identified with 87% of patients exhibiting a trajectory where glucose homeostasis worsened over time. After controlling for age, pancreatic insufficiency, modulator use, and mutation type, there was a significant difference in the study baseline forced expiratory volume in 1 s percent predicted (ppFEV 1) in the high to higher group compared to the low and increasing and low and flat groups ( p < .005). There was high variability of 2hrGlu, but most patients belonged to a trajectory that increased over time. Resultsįor 63 subjects, three unique 2hrGlu trajectories were identified: high (impaired glucose tolerance) to higher ( n = 8), low (normal glucose tolerance ) and increasing ( n = 47), and low (NGT) and flat ( n = 8). Multivariable linear models were used to adjust for clinical covariates. Latent class mixture models were used to determine unique trajectories of 2-h OGTT glucose values (2hrGlu) over time. We conducted a retrospective cohort study of CF patients, ages 10–18 years, without CFRD and with ≥3 OGTT from 2013 to 2016. This study aimed to determine if there were patterns of progression of worsening glucose homeostasis in pediatric CF patients and to explore any relationship to lung function.
Annual oral glucose tolerance testing (OGTT) is the recommended screening modality for cystic fibrosis-related diabetes (CFRD) in patients with cystic fibrosis (CF).
0 kommentar(er)
